YIH
EVFM

Y-Intercept (HK)’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Y-Intercept (HK)’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,254
Closed -$21K – 999
2021
Q2 		$21K Buy
+1,254
New +$23.8K 0.01% 584

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Y-Intercept (HK)'s EVFM Position: Q3 2021 in Review

Y-Intercept (HK) sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2021, closing a stake of 1,254 shares — an estimated $21K sold.

Y-Intercept (HK) first reported a position in EVFM in Q2 2021 and held it in 1 quarter. The position peaked at $21K in Q2 2021. 71 funds tracked by Wall St. Rank hold EVFM as of Q3 2021.

  • Y-Intercept (HK) reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Y-Intercept (HK) sold 1,254 Evofem Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $21K.
  • Y-Intercept (HK) first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Y-Intercept (HK)'s Evofem Biosciences, Inc. Common Stock position peaked at $21K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2021.

Based on Y-Intercept (HK)'s 13F filing for Q3 2021, filed 15 Nov 2021.